市場調査レポート

ティッシュエンジニアリングと細胞移植:米国の皮膚置換と代用品

Tissue Engineering and Cell Transplantation: U.S. Markets for Skin Replacements and Substitutes

発行 Medtech Insight 商品コード 143180
出版日 ページ情報 英文 118 Pages
納期: 即日から翌営業日
価格
こちらの商品の販売は終了いたしました。
Back to Top
ティッシュエンジニアリングと細胞移植:米国の皮膚置換と代用品 Tissue Engineering and Cell Transplantation: U.S. Markets for Skin Replacements and Substitutes
出版日: 2010年12月28日 ページ情報: 英文 118 Pages

当商品の販売は、2016年07月01日を持ちまして終了しました。

概要

皮膚置換と代用製品は現在、ティッシュエンジニアリングの最も有望な応用分野のひとつとなっています。2009年、米国の組織エンジニアド皮膚置換・代用品市場は189億米ドルに達しました。

当レポートは、同市場の2009〜2014年の動向を分析し、新興の製品や治験動向、今後の見通しをまとめ、概略下記の構成でお届けいたします。

エグゼクティブサマリー

第1章 臨床概要

  • 皮膚・サポート組織の層
  • 皮膚置換・代用の主な臨床での応用
    • 火傷
    • 皮膚潰瘍
    • 美容整形
    • 鼠径ヘルニア縫合術

第2章 ティッシュエンジニアリングと臓器再生技術

  • バイオマテリアル
    • 人工バイオマテリアル
    • 生物学的抽出バイオマテリアル
    • ハイブリッドバイオマテリアル
    • 遺伝子組み換えバイオマテリアル
    • 骨格
    • 血管グラフト
  • 細胞培養技術
  • 幹細胞技術
  • 免疫隔離技術

第3章 米国の組織エンジニアド皮膚置換・代用品市場

  • 同種移植片
  • 自己移植片
  • 異種移植片
  • 羊膜
  • 皮膚置換・代用製品
  • 新興製品
  • 市場分析
  • 競合分析

第4章 企業プロファイル

  • Advanced BioHealing, Inc.
  • Cook Biotech, Inc./Cook Group, Inc.
  • Cytomedix, Inc.
  • Integra LifeSciences Corporation
  • LifeCell Corporation/Kinetic Concepts, Inc.
  • Organogenesis, Inc.
  • Soluble Systems LLC
  • Stemnion, Inc.
  • TEI Biosciences, Inc.
  • Wright Medical Group, Inc.

付録:企業リスト

目次
Product Code: A426

Abstract

Skin replacements and substitute products currently represent one of the most promising applications of tissue engineering. In 2009, the potential United States (U.S.) market for tissue-engineered skin replacements and substitutes totaled approximately $18.9 billion, based on a target patient population of approximately 5.0 million. By the year 2019, the total potential target population for the use of tissue-engineered skin replacements and substitutes is expected to increase to 6.4 million, resulting in a potential U.S. market of approximately $24.3 billion in the year 2019. The largest potential area of this market is represented by products for the treatment of diabetic, pressure, and venous ulcers; followed by products for abdominal wall repair, then products for other applications (e.g., dermabrasion site treatment products, fasciotomy site treatment products, Mohs surgery site treatment products, skin graft donor site treatment products, and traumatic wound repair products); and products for burn treatment; face, head, and neck reconstruction; and breast augmentation/repair.

This newest report from Medtech Insight provides the U.S. market forecast for tissue-engineered skin replacement and substitute products for the years 2009 to 2014, an estimation of the potential market for the years 2009 and 2019, and a competitive analysis (including market shares for the leading suppliers to this market). In addition, this new report also provides an overview of tissue-engineered skin replacement and substitutes currently being marketed in the U.S., an update on emerging products as well as a clinical overview of the primary clinical applications for tissue-engineered skin replacements and substitutes (including up-to-date incidence and prevalence numbers for associated diseases).

This is the final report in a series of six Medtech Insight reports covering U.S. tissue engineering and cell transplantation markets. Previous reports in this series have provided analyses of the U.S. markets for cardiac and vascular, musculoskeletal, neurosurgical, urologic, and organ regeneration tissue engineering and cell transplantation products.

Methodology

Reports are produced exclusively by Medtech Insight, through extensive primary and secondary research among the clinicians, researchers, and competitors in the marketplace, and draw upon the industry expertise of a network of industry insiders. Medtech Insight exhaustively corroborates the data as a baseline for completing forward-looking analysis and providing insight into product, technology and market evolution.

Table of Contents

EXECUTIVE SUMMARY

i. Selected Clinical Applications for Skin Replacements and Substitutes

  • a. Burns
  • b. Skin Ulcers
  • c. Plastic Surgery
  • d. Inguinal Herniorrhaphy

ii. Tissue Engineering Technologies

  • a. Biomaterials
  • b. Cell Culture Technology
  • c. Stem Cell Technology
  • d. Immunoisolation Technology

iii. Skin Replacement and Substitute Products

iv. Market Analysis

  • a. Market Drivers
  • b. Market Limiters

v. Methodology

  • Exhibit ES-1: 2009, Potential Caseloads for Tissue-Engineered Skin Replacement and Substitute Procedures
  • Exhibit ES-2: Tissue-Engineered Skin Replacements and Substitutes, Potential Market Forecast, 2009 and 2019
  • Exhibit ES-3: Tissue-Engineered Skin Replacements and Substitutes, Market Forecast, 2009-2014

1. CLINICAL OVERVIEW

  • 1.1 Layers of the Skin and Supporting Structures
    • 1.1.1 Epidermis
    • 1.1.2 Dermis
    • 1.1.3 Subcutaneous Tissue
    • 1.1.4 Fascia
    • 1.1.5 Muscle
    • 1.1.6 Bone
  • 1.2 Selected Clinical Applications for Skin Replacements and Substitutes
    • 1.2.1 Burns
    • 1.2.2 Skin Ulcers
      • 1.2.2.1 Diabetic Ulcers
      • 1.2.2.2 Pressure Ulcers
      • 1.2.2.3 Venous Stasis Ulcers
    • 1.2.3 Plastic Surgery
    • 1.2.4 Inguinal Herniorrhaphy
  • Exhibit 1-1: The Skin' s Layers and Supporting Structures
  • Exhibit 1-2: 2009, Potential Caseloads for Tissue-Engineered Skin Replacement and Substitute Procedures
  • Exhibit 1-3: Stages of Burn Wounds
  • Exhibit 1-4: Stages of Pressure Ulcers
  • Exhibit 1-5: National Nursing Home Survey Regarding Pressure Ulcers

2. TISSUE ENGINEERING AND ORGAN REGENERATION TECHNOLOGIES

  • 2.1 Biomaterials
    • 2.1.1 Synthetic Biomaterials
    • 2.1.2 Biologically Derived Biomaterials
      • 2.1.2.1 Collagen
      • 2.1.2.2 Xenogeneic Tissue
    • 2.1.3 Hybrid Biomaterials
    • 2.1.4 Genetically Engineered Biomaterials
      • 2.1.4.1 Deoxyribonucleic Acid Transfection Vectors
      • 2.1.4.2 Genetically Manipulated Cells
      • 2.1.4.3 Three-Dimensional Polymer Technology
      • 2.1.4.4 Transgenics
      • 2.1.4.5 Fibroblasts
      • 2.1.4.6 Immortalized Neural Stem Cells
      • 2.1.4.7 Gene-Activated Matrices
    • 2.1.5 Scaffolds
    • 2.1.6 Vascular Grafts
  • 2.2 Cell Culture Technology
    • 2.2.1 Bioreactors
      • 2.2.1.1 Flatbed Perfusion Systems
      • 2.2.1.2 Hollow Fiber Bioreactor Systems
      • 2.2.1.3 Cell Suspension Systems
      • 2.2.1.4 Disposable Bioreactors
  • 2.3 Stem Cell Technology
    • 2.3.1 Cell Extraction and Expansion
    • 2.3.2 Bioreactors
  • 2.4 Immunoisolation Technology
    • 2.4.1 Chimeric Immunity
    • 2.4.2 Cell Encapsulation Technology
  • Exhibit 2-1: 2010, Selected Synthetic Biomaterials Used in Tissue Engineering
  • Exhibit 2-2: 2010, Selected Natural Biomaterials Used in Tissue Engineering
  • Exhibit 2-3: 2010, Selected Current and Emerging Cell Extraction, Expansion, and Separation Products and Technologies

3. U.S. MARKETS FOR TISSUE ENGINEERED SKIN REPLACEMENTS AND SUBSITUTES

  • 3.1 Allografts
  • 3.2 Autografts
  • 3.3 Xenografts
  • 3.4 Amniotic Membranes
  • 3.5 Skin Replacement and Substitute Products
    • 3.5.1 Epidermal Equivalents
    • 3.5.2 Dermal Equivalents
    • 3.5.3 Composite Bilayer Skin Equivalents
    • 3.5.4 Other Biological Products for Wound Care
  • 3.6 Emerging Skin Replacement and Substitute Products
    • 3.6.1 Emerging Epidermal Equivalents
    • 3.6.2 Emerging Composite Bilayer Skin Equivalents
    • 3.6.3 Other Emerging Biological Products for Wound Care
  • 3.7 Market Analysis
    • 3.7.1 Market Drivers
    • 3.7.2 Market Limiters
  • 3.8 Competitive Analysis
  • Exhibit 3-1: Advantages and Disadvantages of Allografts
  • Exhibit 3-2: 2010, Selected Dermal Equivalent Skin Substitutes
  • Exhibit 3-3: 2010, Selected Composite Bilayer Equivalent Skin Substitutes
  • Exhibit 3-4: 2010, Selected Emerging Epidermal Equivalent Products
  • Exhibit 3-5: 2010, Selected Emerging Composite Bilayer Equivalent Products
  • Exhibit 3-6: 2010, Selected Other Emerging Biological Wound Repair Products
  • Exhibit 3-7: Tissue-Engineered Skin Replacements and Substitutes, Potential Market Forecast, 2009 and 2019
  • Exhibit 3-8: Tissue-Engineered Skin Replacements and Substitutes, Market Forecast, 2009-2014
  • Exhibit 3-9: 2009, Tissue Engineered Skin Replacements and Substitutes Market, Share by Supplier

4. COMPANY PROFILES

  • 4.1 Advanced BioHealing, Inc.
  • 4.2 Cook Biotech, Inc./Cook Group, Inc.
  • 4.3 Cytomedix, Inc.
  • 4.4 Integra LifeSciences Corporation
  • 4.5 LifeCell Corporation/Kinetic Concepts, Inc.
  • 4.6 Organogenesis, Inc.
  • 4.7 Soluble Systems LLC
  • 4.8 Stemnion, Inc.
  • 4.9 TEI Biosciences, Inc.
  • 4.10 Wright Medical Group, Inc.

APPENDIX: COMPANY LISTING

Back to Top